Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial

Published 2018 View Full Article

Authors

Keywords

Journal

Lancet HIV

Volume 5, Issue 7, Pages e357-e365

Publisher

Elsevier BV

Online

2018-06-19

DOI

10.1016/s2352-3018(18)30092-4

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Ask a Question. Answer a Question.

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started

Lancet HIV

Ask authors/readers for more resources

Protocol

Reagent

Reprint

Find Funding. Review Successful Grants.

Ask a Question. Answer a Question.